Year: 2011
Type: editorial
Abstract: A recurring theme in the way that many pharmaceutical companies approach new technologies is that they are initially extremely enthusiastic, perhaps excessively so, but then subsequently overreact in the opposite direction, abandoning them when the first bumps in the road come along. Only a few years ago, the affection of big pharma for RNA interference (RNAi) seemed unlimited. Merck had acquired Sirna Therapeutics for .1 billion, and Novartis was collaborating with Alnylam, another leading developer of RNAi-based therapeutics.
Source: Molecular Therapy
DOI: 10.1038/mt.2011.94
Author: Arthur M Krieg
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2056546073